Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting in Chicago, Illinois. In addition to reviewing the durable efficacy and safety demonstrated out to 104 weeks in the OPTIC Study, the presentation will include new analyses of intraretinal fluid (IRF) and subretinal fluid (SRF) after a single, in-office, intravitreal (IVT) injection of Ixo-vec in subjects requiring frequent anti-VEGF injections for their wet AMD.
Related news for (ADVM)
- MoBot’s Stock Market Highlights – 09/23/25 11:00 AM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
- Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- adverum biotechnologies appoints jason l. mitchell as chief commercial officer as it prepares to initiate pivotal program